Oramed Pharmaceuticals Inc Cash Flow Conversion Efficiency
Oramed Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Oramed Pharmaceuticals Inc (ORMP) has a cash flow conversion efficiency ratio of -0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($238.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oramed Pharmaceuticals Inc (2005–2025)
Cash flow conversion efficiency of Oramed Pharmaceuticals Inc from 2005 to 2025. This chart illustrates how Oramed Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Oramed Pharmaceuticals Inc share price for real-time trading data and today's change.
Oramed Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Oramed Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oramed Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oramed Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Oramed Pharmaceuticals Inc (ORMP) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vince Holding Corp. Common Stock
NASDAQ:VNCE
|
0.309x |
|
Jarllytec Co Ltd
TWO:3548
|
0.017x |
|
Song Hong Garment JSC
VN:MSH
|
0.042x |
|
Hindware Home Innovation Limited
NSE:HINDWAREAP
|
0.114x |
|
JIUMAOJIU INTL HLDGS LTD
F:3YU
|
N/A |
|
Cnergenz Bhd
KLSE:0246
|
0.031x |
|
Master Ad Public Company Limited
BK:ROCTEC
|
0.025x |
|
Stratus Properties Inc
NASDAQ:STRS
|
-0.045x |
Annual Cash Flow Conversion Efficiency for Oramed Pharmaceuticals Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Oramed Pharmaceuticals Inc from 2005 to 2025. Review cash generation quality of Oramed Pharmaceuticals Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $199.74 Million | $-9.14 Million | -0.046x | +20.89% |
| 2024-12-31 | $145.35 Million | $-8.41 Million | -0.058x | +8.43% |
| 2023-12-31 | $162.89 Million | $-10.29 Million | -0.063x | +66.71% |
| 2022-12-31 | $151.16 Million | $-28.70 Million | -0.190x | -4.45% |
| 2021-12-31 | $116.52 Million | $-21.18 Million | -0.182x | +51.95% |
| 2020-12-31 | $32.88 Million | $-12.44 Million | -0.378x | +43.30% |
| 2019-12-31 | $19.39 Million | $-12.94 Million | -0.667x | -41.64% |
| 2018-12-31 | $31.11 Million | $-14.66 Million | -0.471x | -55.43% |
| 2017-12-31 | $19.24 Million | $-5.83 Million | -0.303x | -270.53% |
| 2016-12-31 | $26.19 Million | $4.66 Million | 0.178x | +189.22% |
| 2015-12-31 | $24.83 Million | $-4.95 Million | -0.199x | -1.82% |
| 2014-12-31 | $20.79 Million | $-4.07 Million | -0.196x | +53.15% |
| 2013-12-31 | $8.13 Million | $-3.40 Million | -0.418x | +31.45% |
| 2012-12-31 | $3.78 Million | $-2.30 Million | -0.609x | -36.17% |
| 2011-12-31 | $3.72 Million | $-1.67 Million | -0.447x | +73.81% |
| 2010-12-31 | $830.27K | $-1.42 Million | -1.708x | -108.25% |
| 2009-12-31 | $2.75 Million | $-2.25 Million | -0.820x | -105.12% |
| 2008-12-31 | $4.59 Million | $-1.84 Million | -0.400x | +66.42% |
| 2007-12-31 | $513.00K | $-611.00K | -1.191x | -242.52% |
| 2006-12-31 | $-432.72K | $-361.61K | 0.836x | -7.39% |
| 2005-12-31 | $-44.81K | $-40.44K | 0.902x | -- |
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for C… Read more